Skip to content
etf.net

PBPH vs THNR

Portfolio Building Block World Pharma and Biotech Index ETF

PBPHBNasdaq

Amplify Weight Loss Drug & Treatment ETF

THNRCNYSE Arca

Overlap

17.3%by weight

Expense ratio

PBPH −0.46pt a year

PBPH0.13%THNR0.59%

Avg volume · 30D

PBPH 93.6×the volume

PBPH138KTHNR1.48K

PBPH vs THNR Performance

Dec 31, 2025 – Oct 30, 2026

+24.2%PBPH+2.9%THNR

Dec 31, 2025 to Oct 30, 2026. PBPH +24.2%. THNR +2.9%. Use the arrow keys to read each point.−5%10%15%20%Dec 2025Jun 2026Oct 2026
Expense ratio
PBPH 0.13%, better
THNR 0.59%
Fund size
PBPH $1.18B
THNR $6M
1Y total return
PBPH No data
THNR +13.2%
Yield (12M)
PBPH No data
THNR 1.59%
Holdings
PBPH 54
THNR 22
Avg volume (30D)
PBPH 138K sh, better
THNR 1.48K sh
NAV per share
PBPH $30.70
THNR $25.95
52W range

ETF.net Grade

PBPH: Cost 94, Risk 56, Mission not scored, Tradability 37, Holdings 40, Durability 51. THNR: Cost 41, Risk 40, Mission 63, Tradability 21, Holdings 65, Durability 18.
Pillar letters and Scores for PBPH, THNR, with each pillar’s weight
PillarPBPHTHNR
Cost30% weightA94HigherC41
Mission25% weightNot scoredB63
Risk15% weightB56HigherC40
Tradability15% weightD37HigherF21
Holdings10% weightC40B65Higher
Durability5% weightC51HigherF18

Rank among Pharma & Therapeutics funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. PBPH and THNR are both graded against the same 9 Pharma & Therapeutics funds, so their Grades compare head to head.

Pharma & Therapeutics⁠

Category · 9 funds
See all 9 ›

PBPH ranks 4th and THNR 7th of 9 funds in the Pharma & Therapeutics Category.

  1. Rank 1APPHVanEck Pharmaceutical ETFScore 74
  2. Rank 2BXPHState Street SPDR S&P Pharmaceuticals ETFScore 67
  3. Rank 3BIHEiShares U.S. Pharmaceuticals ETFScore 66
  4. Rank 4BPBPHPortfolio Building Block World Pharma and Biotech Index ETFScore 65
  5. Rank 5BPJPInvesco Pharmaceuticals ETFScore 63
  6. Rank 6BFTXHFirst Trust Nasdaq Pharmaceuticals ETFScore 57
  7. Rank 7CTHNRAmplify Weight Loss Drug & Treatment ETFScore 44
  8. Rank 8COZEMRoundhill GLP-1 & Weight Loss ETFScore 42

Our read on each fund

ETF.net Research

PBPHBPortfolio Building Block World Pharma and Biotech Index ETF

THNRCAmplify Weight Loss Drug & Treatment ETF

In short

PBPH Most biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.

THNR The GLP-1 trade in one ticker. THNR follows a global index of weight-loss drug developers plus the telehealth and treatment companies the index counts as economic beneficiaries, not just the obvious pharma giants.

Stated mandate

PBPH The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.

THNR The fund provides access to global companies involved in weight-loss drug development or expected to benefit economically from increased use of these treatments, including drug manufacturers and telehealth providers.

Why people hold it

  • PBPH 0.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
  • Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
  • Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
  • Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.
  • THNR Casts wider than the drugmakers: the mandate covers telehealth providers and other firms tied to rising use of weight-loss treatments.amplifyetfs.com
  • Rules-based, not a hunch. It tracks VettaFi's Weight Loss Drug & Treatment Index (THINR), so the lineup changes by published methodology.
  • Global by design, so European drugmakers count as much as US ones. Launched in 2024, as GLP-1 treatments moved from niche to headline.

Worth knowing

  • PBPH One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
  • Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
  • Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.
  • THNR The 0.59% expense ratio runs a touch above what global thematic funds typically charge.
  • A small fund that trades lightly, so spreads can be wider than on big index funds. Limit orders are the usual tool here.
  • One storyline, one drug class. Concentrated by construction, and distributions land annually or semiannually rather than as steady income.

Full PBPH profile⁠

Full THNR profile⁠

PBPH vs THNR Holdings

How PBPH and THNR differ

Overlap by weight

17.3%

Shared holdings make up 27.9% of THNR and 19.2% of PBPH.

Level by level

  • Holdings5 in both17.3%
  • Countryby domicile75.7%
  • Asset classEquity100%

Sector

No Sector split for PBPH.

Country, concentration and asset class

Country by domicile

Country weights in PBPH and THNR, widest gap first
CountryMore in PBPHMore in THNR
United StatesPBPH +11.8 points
ChinaTHNR +11.4 points
DenmarkTHNR +8.9 points
SwitzerlandPBPH +4.7 points
South KoreaTHNR +2.8 points
FrancePBPH +1.8 points
United KingdomPBPH +1.5 points
GermanyPBPH +1.5 points
Other countries (4)PBPH +1.7 points

Outside the US: PBPH 97% developed, 3% emerging. THNR 67% developed, 33% emerging.

Concentration

Weight in the 10 largest Holdings

  • PBPH64.7%
  • THNR66.5%

Securities held

  • PBPH52
  • THNR21

Asset class

PBPH
Equity
THNR
Equity

Holdings

  • Only in PBPH47
  • In both5
  • Only in THNR16

Only in PBPH

47 securities, 80.5% of PBPH by weight

  • Eli Lilly & Co16.78%
  • Johnson & Johnson9.60%
  • Roche Holding AG4.98%

Only in THNR

16 securities, 71.9% of THNR by weight

  • Eli Lilly & Co11.95%
  • Novo Nordisk A/S8.60%
  • AstraZeneca PLC5.91%

Weight gaps

All 5 Holdings in both funds, largest gap first.

Holding weights in PBPH and THNR, widest gap first
HoldingMore in PBPHMore in THNR
Chugai Pharmaceutical Co LtdTHNR +4.56 points
Regeneron PharmaceuticalsREGNTHNR +4.30 points
AbbVie IncABBVPBPH +1.76 points
Amgen IncAMGNTHNR +1.72 points
Merck & Co. Inc.MRKPBPH +0.16 points

All PBPH holdings⁠All 20 THNR holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

PBPH vs THNR Cost

Overpaying THNR vs PBPH

$8,909

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • PBPH 0.13%

    $2,726

  • THNR 0.59%

    $11,635

$10,000
30 years

Cost over time

  • PBPH 0.13%
  • THNR 0.59%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2.5K$5K$7.5K$10K$12.5K051015202530THNR $11,635PBPH $2,726

Year by year

YearPBPHTHNROverpaying
10$238$1,058$820
20$930$4,051$3,121
30$2,726$11,635$8,909

Expense ratio

  • 0.13%PBPH, cheaper
  • 0.59%THNR
  • Middle half of Pharma & Therapeutics funds
  • Median 0.58%

PBPH cheapest of 9 funds

THNR 6th cheapest of 9 funds

PBPH vs THNR Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
PBPH No data
THNR 1.59%
Payout (12M)
PBPH No data
THNR $0.41
Last payment
PBPH $0.02
THNR $0.41
Ex-dividend
PBPH Dec 24, 2025
THNR Dec 30, 2025
Paid on
PBPH Dec 26, 2025
THNR Dec 31, 2025
Frequency
PBPH Irregular
THNR Irregular

Distribution history

Per share, 2024 to 2026, same scale for both

PBPHIrregular · 1 paymentAll PBPH payments⁠
One bar per payment. 1 payment from 2024 to 2026 YTD. Dec 24, 2025 $0.02. Use the arrow keys to read each point.$0$0.252026YTD
THNRIrregular · 2 paymentsAll THNR payments⁠
One bar per payment. 2 payments from 2024 to 2026 YTD. Dec 30, 2024 $0.22; Dec 30, 2025 $0.41. Use the arrow keys to read each point.$0$0.252026YTD

PBPH vs THNR Risk

Fall from peak · 5 years

This chart needs five years of history for both funds.

Risk facts

VolatilityStd dev, 3 years
PBPH No dataTHNR 15.0%since Jun 2024
Return per unit of riskSharpe ratio, 3 years
PBPH No dataTHNR −0.07since Jun 2024
Worst fallMax drawdown, 5 years
PBPH No dataTHNR −32.5%since May 2024
Market sensitivityBeta, 5 years
PBPH 0.05THNR 0.43

Popular comparisons

  • PBPHBvsPPHA

    Portfolio Building Block World Pharma and Biotech Index ETF · VanEck Pharmaceutical ETF

    Expense ratio
    0.13% · 0.36%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • THNRCvsPPHA

    Amplify Weight Loss Drug & Treatment ETF · VanEck Pharmaceutical ETF

    Expense ratio
    0.59% · 0.36%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • PBPHBvsXPHB

    Portfolio Building Block World Pharma and Biotech Index ETF · State Street SPDR S&P Pharmaceuticals ETF

    Expense ratio
    0.13% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • THNRCvsXPHB

    Amplify Weight Loss Drug & Treatment ETF · State Street SPDR S&P Pharmaceuticals ETF

    Expense ratio
    0.59% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • PBPHBvsIHEB

    Portfolio Building Block World Pharma and Biotech Index ETF · iShares U.S. Pharmaceuticals ETF

    Expense ratio
    0.13% · 0.37%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • THNRCvsIHEB

    Amplify Weight Loss Drug & Treatment ETF · iShares U.S. Pharmaceuticals ETF

    Expense ratio
    0.59% · 0.37%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.